Deutsch
 
Hilfe Datenschutzhinweis Impressum
  DetailsucheBrowse

Datensatz

DATENSATZ AKTIONENEXPORT
Zur Ablage hinzufügen
 DetailsÜbersicht
  A meta-analysis of HLA peptidome composition in different hematological entities: entity-specific dividing lines and "panleukemia" antigens

Backert, L., Kowalewski, D. J., Walz, S., Schuster, H., Berlin, C., Neidert, M. C., et al. (2017). A meta-analysis of HLA peptidome composition in different hematological entities: entity-specific dividing lines and "panleukemia" antigens. ONCOTARGET, 8(27), 43915-43924. doi:10.18632/oncotarget.14918.

Item is

 

einblenden: alle ausblenden: alle

Basisdaten

einblenden: ausblenden:
Datensatz-Permalink: https://hdl.handle.net/21.11116/0000-0002-1A1C-3 Versions-Permalink: https://hdl.handle.net/21.11116/0000-0002-1A1D-2
Genre: Zeitschriftenartikel

Externe Referenzen

einblenden:

Urheber

einblenden:
ausblenden:
 Urheber:
Backert, Linus1, Autor
Kowalewski, Daniel Johannes1, Autor
Walz, Simon1, Autor
Schuster, Heiko1, Autor
Berlin, Claudia1, Autor
Neidert, Marian Christoph1, Autor
Schemionek, Mirle1, Autor
Bruemmendorf, Tim H.1, Autor
Vucinic, Vladan1, Autor
Niederwieser, Dietger1, Autor
Kanz, Lothar1, Autor
Salih, Helmut Rainer1, Autor
Kohlbacher, Oliver1, 2, Autor
Weisel, Katja1, Autor
Rammensee, Hans-Georg1, Autor
Stevanovic, Stefan1, Autor
Walz, Juliane Sarah1, Autor
Affiliations:
1External Organizations, ou_persistent22              
2Max Planck Institute for Developmental Biology, Max Planck Society, Max-Planck-Ring 5, 72076 Tübingen, DE, ou_2421691              

Inhalt

einblenden:
ausblenden:
Schlagwörter: RENAL-CELL CARCINOMA; CHRONIC LYMPHOCYTIC-LEUKEMIA; ACUTE MYELOID-LEUKEMIA; RECEPTOR T-CELLS; CANCER-IMMUNOTHERAPY; LUNG-CANCER; SUSTAINED REMISSIONS; CHECKPOINT BLOCKADE; MASS-SPECTROMETRY; MULTIPLE-MYELOMA; hematological malignancies; cancer immunotherapy; tumor antigen; HLA; mass spectrometry;
 Zusammenfassung: Hematological malignancies (HM) are highly amenable targets for immunotherapeutic intervention and may be effectively treated by antigen-specific T-cell based treatment. Recent studies demonstrate that physiologically occurring anti-cancer T-cell responses in certain HM entities target broadly presented non-mutated epitopes. HLA ligands are thus implied as prime targets for broadly applicable and antigen-specific off-the-shelf compounds. With the aim of assessing the presence of common targets shared among different HM which may enable addressing a larger patient collective we conducted a meta-analysis of 83 mass spectrometry-based HLA peptidome datasets (comprising 40,361 unique peptide identifications) across four major HM (19 AML, 16 CML, 35 CLL, and 13 MM/MCL samples) and investigated similarities and differences within the HLA presented antigenic landscape. We found the cancer HLA peptidome datasets to cluster specifically along entity and lineage lines, suggesting that the immunopeptidome directly reflects the differences in the underlying (tumor-) biology. In line with these findings, we only detected a small set of entity-spanning antigens, which were predominantly characterized by low presentation frequencies within the different patient cohorts. These findings suggest that design of T-cell immunotherapies for the treatment of HM should ideally be conducted in an entity-specific fashion.

Details

einblenden:
ausblenden:
Sprache(n): eng - English
 Datum: 2016-08-242016-12-262017
 Publikationsstatus: Erschienen
 Seiten: 10
 Ort, Verlag, Ausgabe: -
 Inhaltsverzeichnis: -
 Art der Begutachtung: -
 Identifikatoren: ISI: 000405498000026
DOI: 10.18632/oncotarget.14918
 Art des Abschluß: -

Veranstaltung

einblenden:

Entscheidung

einblenden:

Projektinformation

einblenden:

Quelle 1

einblenden:
ausblenden:
Titel: ONCOTARGET
Genre der Quelle: Zeitschrift
 Urheber:
Affiliations:
Ort, Verlag, Ausgabe: 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA : IMPACT JOURNALS LLC
Seiten: - Band / Heft: 8 (27) Artikelnummer: - Start- / Endseite: 43915 - 43924 Identifikator: ISSN: 1949-2553